For more than a century, Alzheimer’s disease has been framed as a slow catastrophe that begins inside the brain and stays there until memory and independence are stripped away. A growing group of specialists now argues that this picture is incomplete, and that the earliest sparks of the disease may ignite in the immune system, the liver, or other organs long before neurons begin to die. If they are right, the condition we call Alzheimer’s might be less a primary brain disorder and more a whole‑body breakdown that only later shows up as dementia.
That shift is not a semantic tweak, it is a fundamental reframing of where doctors should look for warning signs and how drug developers should try to intervene. I see it as a move away from chasing plaques in late‑stage brains and toward tracking subtle signals in blood, immune cells, and peripheral tissues years before symptoms appear.
From brain‑first to body‑wide: how the paradigm is shifting
For decades, researchers treated Alzheimer as a disease that begins and ends in the cortex, with amyloid plaques and tau tangles as the main villains. That brain‑first model shaped everything from diagnostic criteria to the design of clinical trials, which typically enrolled people only after memory loss was obvious. Now, a wave of work on hidden biological signals outside the central nervous system is pushing experts to see Alzheimer as a systemic process that may start long before neurons falter, in tissues that quietly feed pathological proteins and inflammatory cues toward the brain.
Investigators studying the roots of Alzheimer have highlighted how peripheral changes in metabolism and immunity can precede cognitive symptoms by years. Researchers describe “hidden biological signals” outside the brain that appear to forecast who will later develop dementia, suggesting that the central nervous system may be reacting to a long‑running disturbance rather than spontaneously degenerating. That perspective helps explain why so many plaque‑targeting drugs have struggled: if the brain is responding to a deeper systemic trigger, then clearing debris without addressing the source is unlikely to deliver lasting benefit.
Immune cells and TREM1: why macrophages are under the microscope
One of the most provocative lines of evidence comes from the immune system, particularly from macrophages, the white blood cells that patrol tissues and clean up damage. In this view, Alzheimer looks less like a purely neurodegenerative process and more like a chronic misfire of innate immunity, where cells meant to protect the brain instead help drive inflammation and toxic protein buildup. I find that shift compelling because it connects dementia to the same immune pathways that underlie conditions like rheumatoid arthritis and inflammatory bowel disease.
Work from Stanford has zeroed in on a receptor called TREM1 that sits on the surface of macrophages and related myeloid cells. TREM1 is described as “almost exclusive to macrophages and to certain other related immune cells, collectively called myeloid cells, that participate in inflammatory responses in the body and, resultingly, in the brain,” a pattern that makes it a prime suspect in the cascade that links systemic inflammation to neuronal injury. In a detailed analysis of TREM1‑positive cells, scientists argue that overactivation of these myeloid pathways could help explain why some people with chronic inflammatory conditions appear to face higher dementia risk, and why dampening specific immune signals might slow or prevent cognitive decline.
That immune‑centric view dovetails with a broader effort at Stanford to rethink Alzheimer’s as a condition that may begin outside the brain, in circulating cells that gradually prime the central nervous system for trouble. By tracking how macrophages respond to injury and infection in the body, and how those responses spill over into microglial activation in the cortex, investigators are building a bridge between peripheral inflammation and the classic pathology seen in autopsied brains. The suggestion that macrophage behavior could be an upstream driver of disease is already reshaping how I think about risk factors like chronic infections, obesity, and cardiovascular disease, all of which are tightly linked to immune dysregulation.
Liver clues and CNS analysis: evidence from outside the skull
If the immune system is one suspect, the liver is quickly becoming another. The organ is central to clearing toxins and managing cholesterol, both of which intersect with amyloid biology, and new work suggests that liver dysfunction might help trigger Alzheimer‑like changes in the brain. In an experimental model that combined metabolic stress with careful central nervous system analysis, scientists found that disrupting liver function was enough to set off early hallmarks of the disease, even before overt cognitive symptoms emerged.
In that study, detailed CNS analysis revealed the presence of intracellular amyloid‑β, often abbreviated iAβ, along with abnormal tau aggregates in pre‑tangle and tangle stages. Those findings are consistent with the earliest pathology seen in human Alzheimer brains, yet here they appeared in the context of liver dysfunction rather than a primary brain insult. The authors argue that such results should push clinicians to consider liver health as part of the workup of patients with dementia, and I would go further: if peripheral organs can seed amyloid and tau pathology, then screening and treating metabolic disease may be as important for brain health as any cognitive test.
Is Alzheimer an autoimmune condition trying to protect us?
Another group of experts is pushing an even more radical idea, that Alzheimer may be an autoimmune disease rather than a straightforward degenerative one. In this framing, the brain is not simply wearing out, it is caught in a self‑directed immune response that starts with a legitimate attempt to repair damage and spirals into chronic attack. That would place Alzheimer in the same conceptual family as multiple sclerosis or type 1 diabetes, where the body’s own defenses become the problem.
Scientists advancing this theory point to beta‑amyloid, the protein that forms plaques, as a key piece of evidence. According to one line of work, beta‑amyloid “acts as an immunopeptide, a messenger within our immune system, so that, if we have head trauma, beta‑amyloid repairs it.” The trouble begins when that repair signal does not switch off, or when repeated insults keep calling beta‑amyloid into action until it accumulates and becomes toxic. This autoimmune interpretation, described in detail in a Jan analysis, reframes plaques not as random junk but as the residue of an overzealous defense system.
Some researchers have gone further, arguing that Alzheimer “might not be caused by degenerating brain cells, but by an autoimmune reaction that mistakenly attacks healthy neurons.” In that view, the disease is “not a brain disease” in the narrow sense, but a systemic immune disorder that happens to manifest most visibly in cognition. Advocates of this model say it could open the door to more effective therapies for Alzheimer’s disease by borrowing strategies from rheumatology and transplant medicine, where clinicians already know how to modulate self‑directed immunity. The idea that Alzheimer is autoimmune remains controversial, but it is forcing the field to ask whether the brain is the victim of a body‑wide misfire rather than the origin of the problem.
Therapies that strike before the brain is overwhelmed
If Alzheimer begins outside the brain, then the most promising treatments may be those that intercept the disease before toxic proteins and immune cells flood the cortex. Drug developers are already starting to pivot in that direction, designing molecules that target peripheral immune pathways and barrier systems instead of only chasing plaques inside the skull. I see this as a pragmatic response to years of disappointing trial results that focused narrowly on late‑stage amyloid removal.
More from Morning Overview